Zamann supports pharmaceutical companies in developing robust Drug Product Risk Management Strategies aligned with ICH M7, EMA, and FDA guidance. Our structured approach provides standardized methodologies, documentation templates, and lifecycle management tools to establish a scientifically justified and inspection-ready framework for managing Nitrosamine (NNO) and NDSRI risks throughout the product lifecycle.
We provide a comprehensive Drug Product Risk Assessment framework that guides the systematic evaluation of formulation- and manufacturing-related nitrosamine risks. The strategy incorporates product information, raw material evaluation, manufacturing processes, scientific justification, and overall risk conclusions to ensure consistent and transparent decision-making.
Our strategy establishes standardized documentation for scientific rationale, regulatory justification, and overall risk evaluation. The framework enables manufacturers to document conclusions consistently, determine whether confirmatory analytical testing is required, and maintain inspection-ready records aligned with current regulatory expectations.
Designed as a living strategy, the framework supports ongoing lifecycle management by allowing risk assessments to be updated as product knowledge, supplier information, manufacturing processes, or regulatory requirements evolve. This ensures long-term compliance while maintaining traceability throughout the medicinal product lifecycle.
Our strategic approach to ensure Nitrosamine compliance is based on global and holistic experience, and can be perfectly adapted to your reality. We address the latest regulations and risk assessments, helping you manage and mitigate potential risks specific to your products and processes.
Zamann stays ahead of the evolving Nitrosamine requirements, providing expert guidance to ensure compliance with confidence. Our proactive and senior approach helps protect product integrity and patient safety, securing your operations against regulatory risks.
